Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences reports 20% bump in 4Q sales, expects continued growth in its main business

Gains were driven by advances in its product and services unit
Lab equipment
The company has increased expenses to bolster sales team

Pressure BioSciences Inc. (OTCMKTS:PBIO), a life-science group that makes laboratory devices, saw a 20% bump in sales for the fourth quarter as its product and services business continues to grow.

Revenue in the period grew to US$502,708, helped by the product and services unit, which expanded by 25%. Revenue for 2017 climbed as well, to US$2.2mln from US$1.9mln a year earlier.

Chief Executive Officer Richard Schumacher said in March that the firm is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc.

READ: Pressure BioSciences chief presents rosy view of growth prospects in podast interview

Pressure BioSciences, which makes instruments that utilize pressure to control bio-molecular interactions, said in a statement Tuesday that accompanied its fourth-quarter earnings that it expects “continued double-digit” growth rates in its product and services business.

“We believe the accomplishments of the past several years have set the stage for future success,” Schumacher said. “We remain very, very excited about 2018.”

While operating loss widened in the fourth quarter, it was on higher expenses linked to expanding the company’s sales team, the Massachusetts-based firm said in a statement. The loss per common share was US$2.37 vs. income of US$3.13 a share in the year-earlier period.

Pressure BioSciences's sales of instruments rose 55% to US$317,498 in the quarter and 21% to US$1.46mln for the full year. Revenue for consumables gained 20% to US$60,108 in the quarter, while it climbed 30% to US$260,331 for the year.

The shares added 1.3% to US$3.80 as of 1:10 p.m. on Thursday.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use